Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Pipeline within a Molecule™
3 Investigational New Drug (INDs) in place with the FDA
Preclinical
Phase 1
Phase 2
Metastatic Castration-Resistant Prostate (CRPC)
Phase 2 trial in combination with Zytiga® (abiraterone acetate)/prednisone – Ongoing
Metastatic Colorectal (mCRC)
Phase 1b/2 trial in combination with FOLFIRI + Avastin® – Ongoing
Acute Myeloid Leukemia – Orphan Drug Designation in the U.S. and Europe
Phase 2 trial in combination with Decitabine – Ongoing
Myelodysplastic Syndrome
Phase 1b/2 Investigator Initiated Trial (commencing Q1’20)
Ovarian, Breast, Pancreatic, Small-Cell Lung
Phase 1b/2 trial ready (Preclinical Data Available)
Leukemias and Lymphomas
Solid Tumors

Recent News

Feb 13, 2020

Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced positive data from its ongoing Phase 2 trial of onvansertib in combination with Zytiga®…

Feb 5, 2020

Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including prostate, colorectal, and leukemia, today announced that a poster featuring efficacy data from its Phase 2 study in metastatic…

Jan 27, 2020

Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company targeting cancers that are both highly prevalent and in need of new effective treatment options including colorectal, prostate and acute myeloid leukemia, today announced positive data from an ongoing Phase 1b/2…